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Nucleotide sequences in three hypervariable regions of the human immunodeficiency virus type 1 (HIV-1) env
gene were obtained by sequencing provirus present in peripheral blood mononuclear cells of HIV-infected
individuals. Single molecules of target sequences were isolated by limiting dilution and amplified in two stages
by the polymerase chain reaction, using nested primers. The product was directly sequenced to avoid errors
introduced by Taq polymerase during the amplification process. There was extensive variation between
sequences from the same individual as well as between sequences from different individuals. Interpatient
variability was markedly less in individuals infected from a common source. A high proportion of amino acid
substitutions in the hypervariable regions altered the number and positions of potential N-linked glycosylation
sites. Sequences in two hypervariable regions frequently contained short (3- to 15-bp) duplications or deletions,
and by amplifying peripheral blood mononuclear cell DNA containing 102 or 103 proviral molecules and
analyzing the product by high-resolution electrophoresis, the total number and abundance of distinct length
variants within an individual could be estimated, providing a more comprehensive analysis of the variants
present than would be obtained by sequencing alone. Sequences from many individuals showed frequent amino
acid substitutions at certain key positions for neutralizing-antibody and cytotoxic T-cell recognition in the
immunodominant loop. The rates of synonymous and nonsynonymous nucleotide substitution in the region of
this and flanking regions indicate that strong positive selection for amino acid change is operating in the
generation of antigenic diversity.
Understanding the nature of sequence change in the
human immunodeficiency virus type 1 (HIV-1) genome is
central to current theories of viral pathogenesis and the
immune response to infection. In common with other eu-
caryotic viruses with RNA genomes, HIV-1 shows consid-
erable sequence diversity between different isolations, par-
ticularly those from geographically distinct regions, where
divergence has taken place over a number of years. Se-
quence diversity is seen within isolations from the same
individual as well as between HIV strains infecting different
individuals (11, 29). The rate of HIV sequence variation is
not uniform throughout the genome. Comparison of pub-
lished sequences has shown that the gag and pol genes are
more conserved than env. Furthermore, within env the
pattern of variation is unusual (3, 34, 38). Five regions in
gpl20, Vl to V5, have been designated as hypervariable (23).
These were defined as regions with 25% or less conservation
of amino acids between a number of published sequences. In
addition to high rates of amino acid substitution, the pub-
lished sequences of some hypervariable regions have been
previously reported to contain short deletions and insertions
(3, 11, 23, 34). Several actual or potential gpl20 epitopes are
located in these regions (23, 34). Antigenic variation conse-
quent to sequence differences in V3 (the immunodominant
loop) has been reported (19, 36). This sequence corresponds
to the predominant neutralization epitope of gpl20 (28), and
it has been argued that the observed variability represents an
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adaptive response by HIV to evade the immune system, as
proposed for equine infectious anemia virus and visna virus
(4, 5, 24). Whether other variable areas of gpl20 are impor-
tant in neutralizing-antibody or T-cell recognition is not
known.
In this work, variation in the gpl20 sequences of provirus
present in circulating peripheral blood mononuclear cells
(PBMCs) was studied. A number of individuals included in
this study were infected from a common source (20), allow-
ing variation between patients to be assessed. The hyper-
variable regions of env not only are polymorphic in sequence
but in many cases also differ in length (3, 11, 23, 34). Thus,
the spacing of the conserved regions of gpl20 shows consid-
erable variation. Using the polymerase chain reaction
(PCR), we have investigated length variation of amplified
DNA in different regions of gpl20 and have visualized
distinctive patterns of coexisting variants in each infected
individual. The data on length variation together with exten-
sive data obtained by sequencing hypervariable regions of
single isolated molecules (30) indicate that the number of
variants present in each patient is extremely large. Despite
this heterogeneity, HIV sequences from individuals in the
hemophiliac cohort, who were infected from a common
source, were clearly more closely related to each other than
to published sequences of HIV-1 and to those of a hemo-
philiac infected in the United States. In particular, the V4
sequence of the cohort members was distinctive and served
to distinguish them from other hemophiliacs.
MATERIALS AND METHODS
Clinical samples. Blood samples were obtained from 11
hemophiliacs infected with HIV-contaminated factor VIII
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approximately 5 years ago (p12 to p95). For sequencing
studies, samples were used from eight haemophiliacs who
were exposed a batch of factor VIII that was implicated in
infection by HIV-1 of 18 out of 32 recipients (20). All eight
individuals seroconverted for antibody between 3 and 10
months after receiving the factor VIII (31). p82 is currently
asymptomatic, and p83 has thrombocytopenia but is other-
wise well; all others have been classified as IVc and suffer
from a range of opportunistic infections and constitutional
symptoms of HIV infection. Samples from individuals in-
fected from other sources include p12, who was infected in
the United States from commercial factor VIII, and 10 drug
abuse-related and pediatric seropositive individuals (nl to
nlO) from J. Mok (Infectious Diseases Unit, City Hospital,
Edinburgh, Scotland).
HIV primers. Oligonucleotides were synthesized by the
Oswel DNA Service, Department of Chemistry, University
of Edinburgh, and were purified by high-performance liquid
chromatography. The primers were based on the consensus
of the following published HIV sequences: HIVHTLVIIIB
(clones HXB2, BH102, and BH8), HIVBRU, HIVCDC42,
HIVELI, HIVMAL, HIVMN, HIVPV22, HIVRF, HIVsc,
HIVSF2, HIVWMJ22, and HIVZ6. The primer-binding sites in
gpl20 were chosen to be as highly conserved as possible
between published sequences of geographical variants of
HIV-1. No more than one mismatch with any of the North
American, Haitian, or African sequences was present in any
one of the primers. The sequences of the primers are given,
with their positions in HIV clone HXB2 indicated in paren-
theses (+, sense; -, antisense): V3 (a) TACAATGTACACA
TGGAATT (+, 6957), (b) TGGCAGTCTAGCAGAAGAAG
(+, 7009), (c) CTGGGTCCCCTCCTGAGG (-, 7331), and
(d) ATTACAGTAGAAAAATTCCCC (-, 7381); V4-V5 (e)
TCAGGAGGGGACCCAGAAATT (+, 7316), (f) GGGGAA
TTTTTCTACTGTAAT (+, 7360), (g) CTTCTCCAATTGT
CCCTCATA (-, 7665), and (h) CCATAGTGCTTCCTGCT
GCT (-, 7814).
Double-PCR method. DNA from at least 5 x 106 PBMCs
was prepared as described by Simmonds et al. (30). Ampli-
fication of DNA by double PCR and quantification by
limiting dilution were carried out as described by Simmonds
et al. (30). All DNA extractions and amplification reactions
carried appropriate parallel negative controls (blood from
seronegative, low-risk group blood donors) to detect con-
tamination at any stage in the procedure. In principle, at
least five outer primer pairs may be used simultaneously in
the first amplification reaction. However, DNA sequences
amplified by the outer V3 and V4-V5 primers overlap. To
permit the same sample to be amplified in the two regions,
the following combinations of primers were used. In the first
reaction, positive-sense, outer V3 primer (primer a; see
above) was used with the antisense, outer V4-V5 primer
(primer h), to amplify a 858-bp fragment; in the second
reaction, a sample of the product was amplified by using the
inner V3 (primer b) and inner V4-V5 (primer g) primers (657
bp); in the third reaction, the final amplification used the
inner V3 (b plus c) and V4-V5 (f and g) primers in separate
reactions. This modified procedure is equivalent in sensitiv-
ity and yield to separate amplification in two stages by
double PCR (data not shown).
Length analysis of PCR products. To investigate length
variation in product DNA amplified in the three env regions,
the final PCR reaction was carried out in the presence of 0.05
to 0.1 ,uCi of [cI-355]thio-dATP (1,000 Ci/mmol; Amersham)
and 8.3 mM each of unlabeled deoxynucleoside triphos-
phates (dNTPs). A 1-,ul sample of the PCR product was
heated to 95°C in 50% formamide for 3 min and electro-
phoresed on a denaturing polyacrylamide gel (6% acryl-
amide, 0.3% N',N bisacrylamide, 8 M urea, 0.089 M Tris,
0.089 M boric acid, 0.002 M EDTA, pH 8.3). Standard DNA
size markers (1,635, 1,018, 516, 506, 394, 344, 298, 220, 200,
154, and 142 bp; BCL) were end labeled with [_y-32P]dATP.
Gels were dried and exposed overnight on X-ray film.
Analysis of migration distances and intensity of bands was
assisted by the use of a densitometer.
DNA sequencing of PCR products. The double-PCR pro-
cedure produces sufficient DNA from single isolated mole-
cules of target sequence to permit direct sequencing of the
PCR product (30). Unreacted dNTPs and primers were
removed from product DNA by using Gene-Clean (Bio 101,
Inc.). Direct sequencing was then carried out by using one of
the primers used for the final amplification by the Sequenase
protocol (U.S. Biochemical Corp.), with the following mod-
ifications: the standard annealing mix was adjusted to 10%
dimethyl sulfoxide (40), and the sample was denatured by
boiling for 5 min and immediately chilled on ice. The labeling
reaction was performed at room temperature for 5 min with
0.25 ,uM two unlabeled dNTPs and 5 ,uCi of al-35S-labeled
dATP or dCTP (1,000 Ci/mmol; 37). The choice of unlabeled
and labeled dNTPs was based on the nucleotides present 3'
to the priming site used. Termination reaction mixtures
contained a final concentration of 10% dimethyl sulfoxide.
Sequences were analyzed on a 6% polyacrylamide wedge
sequencing gel.
Nucleotide sequence accession number. All sequences used
in this study have been submitted to GenBank (accession
number M36997).
RESULTS
Amplification of HIV provirus by PCR. Two different
approaches to PCR amplification were used. In the first, a
sample of DNA large enough to contain a representative
sample of provirus was amplified. In this case, the product
should be representative of the provirus population in the
sample (see below). In the second method (30), single
molecules of provirus were isolated by dilution before being
amplified. In this case, the product of each amplification
derives from a single provirus. In many cases, a double-PCR
reaction using nested primers was used. In this method, a
small sample of the first PCR reaction is used to prime a
second (30). Consequently, the products of a first amplifica-
tion can be used to prime more than one amplification, for
example, one with labeled precursor for visualization by
autoradiography and a second without labeled precursor for
direct sequencing (see below).
In published HIV-1 sequences, the length of the region
amplified by the V4-V5 primers (spanning V4, C3, and V5;
23) varies by as much as 30 of around 300 nucleotides.
Substantial size variation in this region is also found within
the provirus population present in a single infected individ-
ual. For example, a sample of DNA from hemophiliac p79,
containing about 60 molecules of provirus (30), was ampli-
fied with the V4-V5 primers and labeled with [a-35S]thio-
dATP during the second amplification step. When analyzed
by gel electrophoresis, the product showed a complex set of
size variants (Fig. 1, lane U). To confirm that these were
natural variants present in the DNA sample rather than
artifacts of the PCR reaction, single provirus molecules were
isolated by dilution before amplification (30). A total of 31
replicate tubes, each containing 625 cell-equivalents of
DNA, were amplified in the double PCR, with [a-35S]thio-
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FIG. 1. Size analysis of amplified proviral DNA in the V4 and V5
regions from PBMCs of an HIV-infected individual (p79). Positive
reactions at limiting dilution of PBMC DNA from an HIV-infected
hemophiliac (p79) were amplified with V4-V5 primers and electro-
phoresed on a polyacrylamide gel (lanes 1 to 13). Lane U, 1 ,ug of
PBMC DNA from p79; lane M, product size estimated with DNA
markers of sizes (in nucleotides) indicated (see Materials and
Methods); lane N, 1 ,ug of PBMC DNA from an uninfected individ-
ual.
dATP added to the second reaction. Thirteen of the reac-
tions were positive. From the 18 negative reactions, the
Poisson formula predicts that approximately 75% of the
positive reactions are due to the amplification of a single
provirus molecule. Electrophoretic analysis of the positive
reactions showed that the length variants found by amplify-
ing 60 provirus molecules together were also found when the
molecules were isolated before amplification (Fig. 1, lanes 1
to 13). A single lane (lane 5) clearly contained two length
variants, consistent with the prediction of the Poisson for-
mula.
To determine the basis of the length variation, the prod-
ucts of 12 of the 13 first PCR reactions (omitting reaction 5)
were again amplified in the second PCR but without labeled
substrate and directly sequenced (30). The 12 nucleotide
sequences are shown in Fig. 2. The lengths of the amplified
sequences calculated from electrophoretic analysis agree
well with the lengths determined by sequencing (Fig. 2, last
two columns). Thus, the differences in electrophoretic mo-
bility reliably reflect differences in length.
The isolated molecules appeared to be a random sample of
the sequences visualized in the bulk amplification of 60
provirus molecules (Fig. 1, lane U). Thus, the four more
intense bands in lane U with lengths of 296, 299, 302 and 305
nucleotides were represented by one, one, six, and two
isolated sequences, respectively. Faint bands with lengths of
284 and 293 nucleotides were represented by one isolated
sequence, and others with lengths of 287 and 281 nucleotides
were not represented. Thus, the analysis of bulk samples
provides a convenient and rapid assessment of the spectrum
of size variation within the provirus population present in a
DNA sample.
Amino acid sequence variation in HIV-infected individuals.
PBMC DNA from eight other infected individuals was
diluted and sequenced in the V4 and V5 regions as described
for p79, in all cases using low frequencies of positive
reactions at limiting dilution to avoid multiple positives. To
simplify the presentation, the nucleotide sequences were
translated. Figure 3 shows alignments of such amino acid
sequences obtained from each individual. Considerable di-
versity in the V4 and V5 regions was seen within and
between individuals. In many individuals, it was necessary
to insert notional gaps to preserve alignment of the se-
quences. These gaps were concentrated exclusively in the
V4 and V5 regions, where there was also a high rate of amino
acid substitution. Each gap was a multiple of 3 nucleotides,
maintaining the reading frame of the sequence. The degree of
sequence variation within an individual varied considerably,
the sequences from p77 and p79 showing the most hetero-
geneity in this group and those from p84 showing the least.
A number of sequences showed short repeats of 3 to 6
amino acids in V4 and V5 (Fig. 3). The same repeated
sequences were found in different individuals. In V4, se-
quences containing (N)STW were repeated in p74, p77, and
p82, while p77, p79, p83, p84, p87, and p91 showed repeats
of sequences TTGSN and TTESN. In V5, repeats of NET
were found in two individuals, p77 and p12. The number of
repeated sequences varied both between and within sam-
ples. This duplication of sequence motifs accounts for some
of the observed length variation. Sites for potential N-linked
glycosylation sites were concentrated in the hypervariable
regions. In each individual, there was a concentration of
potential N-linked glycosylation sites in the V4 and V5
regions. The number and positions of such sites were vari-
able between individuals and within each patient sample
(Fig. 3). Variation in the number of repeats changed the
overall potential for carbohydrate addition in this region of
gpl20 (Fig. 3).
Length polymorphism of DNA amplified in the V4 and V5
regions. With the exception of p82, few identical sequences
Seq. < V4- > < C3 > <------------ V5 ------------- > <-
Sequence Measured
C4 Length (bps) Length (bps)
1 51 bps +
2 51 bps +
3 51 bps +
4 51 bps +
6 51 bps +
7 51 bps +
8 51 bps +
9 51 bps +
10 51 bps +
11 51 bps +
12 51 bps +
13 51 bps +
Cons 51 bps +
+ 132 bps +
+ 132 bps +
+ 132 bps +
+ 132 bps +
+ 132 bps +
+ 132 bps +
+ 132 bps +
132 bps +
+ 132 bps +
+ 132 bps +
+ 132 bps +
+ 132 bps +
+ 132 bps +
+41 bps =
+41 bps =
+41 bps =
+41 bps =
+41 bps =
+41 bps =
+41 bps =
+41 bps =
+41 bps =
+41 bps =
+41 bps =
+41 bps =
302
302
293
305
302
284
302
305
302
302
296
299
303.4
302.7
294.3
306.3
303.0
285.1
302.0
305.8
302.0
302.0
295.8
300.1
+41 bps = 305
FIG. 2. Alignment of sequences obtained by limiting dilution of PBMC DNA from p79. Sequence labels V4, C3, V5, and C4 follow
previous usage (23). Symbols: ., unsequenced; -, gap introduced to preserve alignment; ?, no majority consensus. Sequences 1 to 13
correspond to lanes 1 to 13 in Fig. 1. Differences from the consensus are indicated in lowercase.
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FIG. 3. Alignment of sequences from nine hemophiliacs in the V4 and V5 regions. Individual sequences from each individual are indicated
as a to z. Symbols: not sequenced; -, gap introduced to preserve alignment; #, asparagine residue site of potential N-linked glycosylation;
?, no majority consensus at this position; *, stop codon. Conserved amino acids are shown in uppercase; nonconserved amino acids are shown
in lowercase. Tandem repeated sequences are indicated by boxes. Potential glycosylation sites shown whether conserved or not.
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FIG. 4. Size analysis of amplified proviral DNA in the V4 and VS
regions from PBMCs of HIV-infected individuals. Samples (1 jig) of
PBMC DNA from HIV-infected nonhemophiliacs (nl to nlO) and
hemophiliacs (p74 to p95) were amplified with V4-V5 primers and
electrophoresed on a polyacrylamide gel. Lane M, Product size
estimated with DNA markers of sizes (in nucleotides) indicated (see
Materials and Methods).
were isolated from the same individual (Fig. 3). No two
identical sequences were isolated from p12, p79, p83, p87, or
p91; p74 and p77 each had two identical sequences, p84 had
three, and only p82 and p87 had multiple incidences of two
sequences. Clearly, the sequences determined do not repre-
sent the full range of variation present in most of the
individuals studied. It would be possible in principle to
sequence each DNA sample exhaustively. However, a sim-
pler approach to the question of variation within and be-
tween individuals is to use the PCR technique described
above to assess the profile of length variation in each sample.
The length analysis can be carried out with a standard
amount of PBMC DNA, so that many samples can be dealt
with rapidly.
To demonstrate the range of length variation within PBMC
samples, 1-,ug samples of DNA from 18 HIV-infected indi-
viduals were amplified by using the V4-V5 primers as
described above (Fig. 4). The samples compared were from
p74, p77, p79, and p82, and the number of provirus mole-
cules present in the 1-,ug samples ranged from 60 (p79) to 200
(p82; 30). A close concordance was observed between the
sizes of the bands measured by gel electrophoresis and sizes
determined by sequencing isolated molecules from the same
sample ofDNA (Table 1). For example, the prominent bands
in the p74 and p82 samples with estimated sizes of 308.0 and
316.5 bp were paralleled by a predominance of sequences
with overall lengths of 308 and 317 bp. Similarly, the wide
range of band lengths observed upon amplication of the p77
sample was paralleled by a wide range of lengths among the
individually determined sequences. These data show that an
analysis of length variation serves as an approximate mea-
sure of the overall sequence variation in a provirus popula-
tion. The sequence data (Fig. 3) show that a length variant
may comprise several different sequence variants. For ex-
ample, sequences 74-a, -b, and -c had the same overall length
as 74-e and -f, although the two groups differed in the
positions of the gaps and a number of amino acid substitu-
tions. An impression of the large range of variation which
can occur within a sample may be gained by considering the
range of size variation and the number of sequences of a
given length together. In several cases, this must represent a
tremendous amount of variation in the V4-V5 region alone.
Band lengths overved in the V4 and V5 regions with
samples from eight hemophiliac patients are summarized in
Table 2. Data from 10 drug abuse and pediatric patients are
also listed for comparison. The overall range of lengths and
patterns were similar in the two groups. The majority of
samples contained bands in the range of 293 to 317 bp, but
there was considerable variation in the diversity of bands
present in a sample. At one extreme, n3 and p77 had 10 and
13 bands, respectively, with ranges of 287 to 317 and 287 to
326 bp. At the other extreme, n6, n7, and p95 had single
bands of 296, 314, and 293 bp. The range of lengths of the V4
and V5 regions of geographically diverse isolated HIV-1
sequence variants, from 293 (HIVSF2) to 311 (HIVCDC42),
lies within the range observed in this study and suggests
possible selective constraints on the size of these regions.
Sequence variation in the V3 hypervariable region. To
investigate sequence variability of the immunodominant
loop (28), sequences of individual provirus molecules in the
PBMC DNA samples were determined with the V3 primers
TABLE 1. Comparison of size of amplified DNA with overall lengths of sequences obtained by limiting dilutiona
p74 p77 p79 p82
Amplified No. of Amplified No. of Amplified No. of Amplified No. of
DNA sequences DNA sequences DNA sequences DNA sequences
325.1
322.5 1 at 323
316.6 1 at 317 316.5 8 at 317
313.7 2 at 314 313.7 1 at 314
311.2 311.7 1 at 311
310.0 5 at 308 308.3 2 at 308 306.9
305.1 305.1 2 at 305 304.0 2 at 305
301.2 302.0 301.65 6 at 302 301.3
299.2 1 at 299 299.9 1 at 299
295.5 1 at 296 296.5 298.1 1 at 296
293.8 1 at 293
290.7
288.0 288.0 2 at 287
1 at 284
a Prominent bands are in bold type; all sizes are given in base pairs.
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TABLE 2. Distribution of length variants in the V4 and V5 regions
Intensity of bandb at observed size (bp) of:
Samplea
287 290 293 296 299 302 305 308 311 314 317 320 323 326
nl 3 3 1 2 1
n2 3 3 3
n3 1 2 1 3 3 1 1 2 1 1
n4 2 2 1 5 1
n5 1 1 3 3 1 2
n6 5
n7 5
n8 2 2 2 1 2 2 1 1 2 1
n9 5 2
nlO 1 1 5 1 3 1
p74 1 2 1 2 4 1
p77 1 1 2 1 2 1 2 2 1 1 2 1 1
p79C 1 1 3 2 3 2
p82 1 1 2 1 1 4
p87 2 3 3 2 1
p91 1 3 3
p89 1 2 3 3
p95 5
a nl to nlO, HIV-infected nonhemophiliac individuals; p74 to p95, hemophiliacs.
b Scored on a scale of 1 (weak) to 5 (strong).
c Bands (intensity = 1) also at 284 and 281 bp.
(Fig. 5). Sequences bearing the same identification letter in
Fig. 3 (V4 and V5 sequences) and Fig. 5 (V3 sequence) were
derived from the same provirus molecule (see Materials and
Methods). Sequence variation accompanied by little length
variation was the dominant feature of the sequences of V3
and flanking regions (Fig. 5). The sequence diversity within
a sample was no less than in the V4 and V5 regions.
However, in the V3 region, each sample showed particular
sequence features, often common to all sequences within a
sample, which distinguished it from other samples. Over the
V3 region as a whole, only 23 of 83 amino acids were
conserved in all of the sequences listed in Fig. 5. The
immunodominant loop sequences all differed considerably
from the prototype HIVMN and HIVHTLVIIIB (clone HXB2)
sequences and from those of other geographical HIV-1
variants (Fig. 5). The core sequence GPGR was well con-
served between individuals, although a number of variants
existed. However, in one individual (p12), the majority of
sequences were GSGR.
The flanking regions of V3 contain a large number of
potential N-linked glycosylation sites. There are six of these
in the prototype HIVHTLVIIIB sequence in Fig. 5, and there
are six potential sites for N-linked addition lying to either
side of the V3 loop structure. No glycosylation sites are
common to all of the sequences. By contrast, the two
cysteine residues spanning the immunodominant loop are
absolutely conserved (Fig. 5).
DISCUSSION
Diversity of env sequences within HIV-infected individuals.
A striking feature of the proviral sequences reported here is
the diversity of env sequences within a number of the
individuals studied. In many cases, there is a complete lack
of homology between variants over a number of amino acid
residues (for example, the V5 region of p79). It is clear that
a very considerable amount of sequencing would be neces-
sary to describe fully the range of variation in proviral
sequences within PBMCs. The visualization of length vari-
ants in the V4 and V5 regions provides a rapid method for
the partial characterization of sequence variants within a
sample. Analysis of the amplified DNA from samples con-
taining large numbers of proviral sequences shows the range
and relative abundance of sequences that differ in length.
The niethod provides evidence for the existence of relatively
scarce sequences that were not detected by conventional
sequence analysis of a relatively small number of variants.
The method does not provide comparative sequence infor-
mation on the different length variants, and each length
variant comprises an unknown number of distinct se-
quences. However, it provides a simple description of the
provirus population which allows large numbers of individ-
ual samples to be compared. Applications include the anal-
ysis of sequence change over time in an individual (P.
Simmonds, unpublished data) and comparisons between
proviral variants in PBMCs and viral RNA in plasma (L.-Q.
Zhang, personal communication). It also allows genuine
positive PCR results from patient screening to be distin-
guished from those due to contamination by cloned se-
quences (39).
Phylogenetic significance of amino acid changes in env.
Many hemophiliacs treated with commercial factor VIII in
the early 1980s became infected with HIV-1. The rate of
infection was considerably lower in those who were treated
with factor VIII prepared from plasma of volunteer blood
donors in a low-prevalence area for HIV-1 infection, such as
Scotland (21). However, some hemophiliacs treated in Ed-
inburgh solely with locally produced factor VIII were in-
fected with HIV-1 in 1984 (20). A single batch of factor VIII
has been implicated in the infection of 18 hemophiliacs,
including hemophiliacs p74, p77, p79, p82, p83, p84, p87,
and p91 studied here. p12 was infected in the United States
from commercial blood products.
The V4 regions of six of the eight designated cohort
members (p77, p79, p83, p84, p87, and p91) are very similar
to each other, and all contain two repeats of a relatively well
conserved 5-amino-acid sequence, TTGSN. p77 and p79
contain variant proviral sequences that lack one of the two
copies of this sequence, while some variants from p77 have
a second copy of the preceding LFNSTW sequence. How-
ever, p82 and p74, who were also considered to be infected
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77-al kdp # t s# s h --a v hat e i di # kd # vt e#- N
77-di kdp # t s# s h-- v hat e i di #L d # vt e#- N
77-i kdp # t s# s h-- v hat e i di #L g # n vk k N- #
77-f kdp # t s# s h --a v hat e i di N kd # vt k N- #h
77-m #n t s# s h-- v hat e i di sL ed # vt e#- #
79-m #e v # s h-- yat e t i #l e # vt k#- #
79-n #e v i N s pm-- ks yat d ii l e # vt k #-r #
87-a kdp k # g#y e s-- arrq i di k e # r vt k k#- NI
87-b kdp k # g#y e s-- arrq i di k e # r vt k e#- NI
87-c kdpk# g#y e s-- arrq i di k e # r vt k e#- #
87-d kdp k g# e s-- ar q i di k e # r vi k d#- #
87-e kd k# s# ss-- yat e i di #l e tk vte k r#- k #
87-f kd s# s s-- yat e i di #L e # r ai k k#-r # a
87-g kd s# s s-- yat e i di UL a # r ai k kf-r k #
87-hi kd s# s s-- yat e i di #L a # r ai k k#-r k #
91-a . k g# s-- atsq i di k #L ee # vt
91-b k p k # g# s-- atsq i di k #L ee # vt k#- n..
91-c . k # g# s p-- atsq i di k # ee # vt
91-d . k # gd srn-- yat d i di #L ee dd vt k
91-e. k # g# s P-- yat d idi #L ee dd vt ..............
82-c #e v t y-- vy teq ii #e vi e#-
82-d #e v t y vy teq i i U #e vi e#-
82-e #e v # h-- vy teq i U #e vi e - a
82-f #e v i y v teq ii N #e vi eN-
82-g #e v i # y vy teq ii #e vi e#-
82-h #e v # g h-- s yat g i di #e vt k#- #
82-i #e v# # g h-- s yat g i di N #e vt k#- U
82-j #a v t h-- vy t q i di #L #e r vi g t k r
74-a #e v # rg h-- yat n i di t #d vt #-S #f
74-b #e v # rg h-- yat n i di t #d vt #-s
74-d t #e v # g# rs h --wm yat e i di Ut i vt V#- #f
74-f #e v # # rgh-- yaar i di #L t #d h vt r#-r gr
74-g #e v # s# rg h-- yat n i di t #d vt #-s t
12-b #n U sk i rs h --s y eg a dv k y tL#gt #d lva - q p
12-c #n # sk i rsmh --s y eg a dv k y tL#gt #d Lva - q p
12-d #s N s k rsh --s y eg t dv k y tL#gt #d L va - t p
12-e #n s#t rs h-- y t e t dvek y tL#gt #d L va - k qp
MN h #e q # y k h-- y tkn i ti # #d r v k k-
RF #a q # N s tk-- viyat q i di k UL q # vt d#- ts
SF2 #e aN # s y -- h t r i di k q # e vk # UJ
HXB2 TIIVQL#TSVEI#C TRPN#NTRKRIRIQRGPGRAFVTIGKI -GNMRQAH C#ISRAKW#NTLKQIDSKLREQFGN#KTIIFKQSS|
I--- IMMUNODOMINANT LOOP---------
FIG. 5. Alignment of sequences obtained from seven hemophiliacs in the V3 and flanking regions. Individual sequences are indicated as
a to z. Symbols are as for Fig. 3. Differences from the pHXB2 sequence are shown in lowercase. All potential N-linked glycosylation sites
are shown.
from the same source, contained proviral sequences in this
area that were distinct from each other, from those of the
other cohort members and p12, and from published se-
quences (Fig. 6A). However, at the time of seroconversion,
the V4 sequences of both individuals were similar to those
reported here for the two individuals (Zhang and Simmonds,
unpublished observations). This finding rules out the possi-
bility that a higher rate of sequence change of HIV in these
two individuals was responsible for the current dissimilari-
ties in V4 sequences from the rest of the cohort. At present,
it is not clear whether several strains of HIV-1 were present
in the same contaminated batch of factor VIII or whether
p82 and p74 were infected from a different source altogether.
There is no evidence for other risk factors for HIV infection
in either hemophiliac. The most likely sources are other
infectious batches of locally prepared factor VIII concen-
trate. V4 sequences similar to those of p82 have been found
in another hemophiliac (data not shown) who was not treated
with the implicated batch of factor VIII but who did receive
several other locally produced batches that were also given
to p82.
In contrast to the similarities observed in the V4 region, no
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A
p77 |StWLFNSTW|Nd TTesN tTeS? NtEpIt
p79 STw Nd ttGSn tTGSN nTEpIT
p83 STW ND TTGlN iTGSN N?gnIT
p84 STW ND TTGSN TTGSn NTETIT
p87 STW Nd TteSN TTgSN NnEtIT
p91 STW ND tTgsN tTgSN NTEiIt
p82 STW nst| DltqtNSTQ-NkeEN IT
p74 STW NN?DTSTWNK?eESgN IT
p12 SNW StSPGEpNNTTGN-- IT
HXB2 STUWFNSTW|S S NN ji DT IT
RF STW NSTEGSNNTGGNDT IT
SF-2 NTW RLNHTEGTKGNDT II
B
p77 DGG rn[N eieITEtI
p79 dGg kn?s??-t ET
p83 DGG ?egN?T E.
p84 DGG -ENR?eT E.
p87 DGG ?ngnk?e? Ei
p91 DGG gsNss--N ET
p82
p74
p12
HXB2
RF
SF-2
DGG NSgnksndTT Et
DGG tEn?-TENRtT El
DGG ?-Ne iI Ei
DGG NSNNES ET
DGG E DTT NTT El
DGG T NVT NT EV
C
p77 TIIVQLkdpVnITC TRPSNNTRKSIHI--gPGRVFHATGEIIGDIRQAH CnLSR?dWNNTLkQIVtKLrEQFeN-KTIIFNqSSI
p79 TIIVQLNESWINC ?RPNNNTRKSI??--GPG??FYATG?I?GNIRQAH CNLSRAEWNNTLKQIVTKL?EQF?N-?TIIFNQSSI
p87 TIIVQLKDpVkINC TRPgNnTRerISI--GPGRAF?A?g?IIGDIRQAH CN?S?AeUnnTLrQIv?kLKEQF?N-kTiIFNQSs
p91 TIIVQLKNPVKINC TRPGnNTRKsIpI--GPGRAFvATsqIIGDIRkAH CNLSREEWnnTLKQIVTKLrEQFKN-KTIIFN...
Cons TIIVQLkdpV?InC tRP?nnTRksl?i--gPGraF?Atg?IiGdlRqAH CnLSraeWnnTLkQIvtkLkEQF?N-kTiiFNqSs
Cons TIiVqLNeSVvInC tRPnrntRk?ihi--gpGrafyttg?IiGdirqAh CnisrakWn?TLkqIv?KLrEQF?n-ktliF?qSS
p82 TIIVQLNeSWInC tRPNNNTRKrI?I--GPGrAvYtTeqIIGnIRQAH CNiSRAKWNETLkQIViKLrEQFen-KtIVFkqSS;
p74 TIiVQLNESWINC TRPnNNTRRgIHI--gpGRAFYAtgnIIGDIRQAH CNiSRTKWndTLKqIVTKLREQFgN-sTIVFnqSSI
p12 TIIVQLNnSVEINC TRPS?n?RRS?HI--GsGRAFYTiegI?GDVrKAY CTLNGTKWNDTLKLIVAKLREQFGN-KTI?FkPSSI
MN TIIVHLNESVQINC TRPNYNKRKRIHI--GPGRAFYTTKNIIGTIRQAH CNISRAKWNDTLRQIVSKLKEQFKN-KTIIFNQSS
RF TIIVQLNASVQINC TRPNNNTRKSITK--GPGRVIYATGQIIGDIRKAH CNLSRAQWNNTLKQIVTKLREQFDN-KTIIFTSSS
SF2 TIIVQLNESVAINC TRPNNNTRKSIYI--GPGRAFHTTGRIIGDIRKAH CNISRAQUNNTLEQIVKKLREQFGNNKTIIFNQSS
HX82 TIIVQLNTSVEINC TRPNNNTRKRIRIQRGPGRAFVTIGKI-GNMRQAH CNISRAKWNNTLKQIDSKLREQFGNNKTIIFKQSSJ
FIG. 6. Comparison of hemophiliac and published sequences in the env hypervariable regions V4 (A), V5 (B), and V3 (C). Consensus
sequences from individuals believed to have been infected from a common source (p77, p79, p83, p83, p87, and p91) are compared with those
of apparently unrelated sequences (p82 and p74), those of a hemophiliac infected from commercial factor VIII, and published sequences.
Differences from the consensus within infected individual are indicated in lowercase. ?, No majority consensus at this position in an individual
or group consensus sequence.
relationship between the cohort members is apparent in V5
(Fig. 6B), where sequence variation is much greater. The
rate of sequence change in the short V5 region appears more
rapid and does not indicate any relatedness between the six
individuals who have similar V4 sequences. The V3 regions
of the members of the hemophiliac cohort differ from the
reference HXB2 sequence by a number of amino acids.
However, no clear relationship distinguishes the cohort
sequences. This is shown by the similarity in the consensus
of the four confirmed cohort members and the combined
consensus of noncohort members p12, p74, and p82 and
published sequences (Fig. 6C). There are only five differ-
ences between the consensus sequences of the two groups,
and at all but one of these sites, variants within the con-
firmed cohort members exist that match the noncohort
sequences (Fig. 6C).
Nature of variation in the hypervariable regions of env.
Both amino acid substitutions and gaps contribute to varia-
tion in the V4 and V5 regions. Many of the gaps in V4
involve repeated sequences such as TTGSN (p77 and p79).
In such cases, some variants have one copy while others
have two. Similar variation in the numbers of copies of the
sequence (F)NSTW may also be found in p77. Indeed, the
existence of repeats of these two sequences in most individ-
uals indicates that some sort of duplication event has taken
place. In many sequences, there are minor differences be-
tween the two copies, suggesting that some sequence change
has taken place after duplication. The exact sequence in-
volved in a duplication event may differ. For example, the
block NSTW is repeated in p82, while in p77 there is often a
repeat of the longer sequence LFNSTW. In published se-
quences of the viral isolated HIVHTLVIIIB, the BH8 clone
has one copy of the sequence FNSTW, while others (for
example BH10) have two. The widespread occurrence of
these repeated sequences (3, 11, 23, 34) and the likelihood
that they occur independently in different HIV-infected
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individuals suggest that this sequence is predisposed to
duplication during either reverse transcription or RNA syn-
thesis. Furthermore, if duplication is occurring repeatedly in
the samples that we have examined, it is also likely that once
formed, the duplications are predisposed to deletion.
All of the insertions or deletions in the V4 and V5 regions
are multiples of 3 nucleotides, thus maintaining the reading
frame downstream. Similarly, only one chain termination
mutation (p79, sequence 1; Fig. 3) was found in 37 V3
sequences and 71 V4 and V5 sequences. The low rate of
inactivating mutations is consistent an absence of pheno-
typic mixing. This finding may reflect the low copy number
(close to one) of provirus in infected PBMCs (30).
Positive selection for sequence change in hypervariable
regions of env. There has been no satisfactory explanation of
the high rates of mutation in localized regions of the env
gene. It could be argued that the cause is simply a lack of
functional constraints which might limit the amount of
variation in regions such as the CD4 binding site (6, 16).
However, this view is not supported by a comparison of the
rates of synonymous and nonsynonymous substitution rates
in the different regions of env. Published data and data
collected in this laboratory (P. Balfe et al., unpublished data)
give a ratio of synonymous to replacement substitutions
(KsIKa ratio; 18) for the CD4 binding site of 1.24. For
comparison, the Ks/Ka ratio for gag sequences (17) and
those of samples studied here is about 6.7, and the ratio for
42 eucaryotic genes is 5.28 (18). Thus, the CD4 binding site
does not appear to be under stringent constraint to maintain
its amino acid sequence, and the much higher substitution
frequency of the hypervariable regions cannot simply be due
to lack of constraint. The KsIKa ratio for the sequences
reported here of the V3 loop and flanking regions is 0.67,
lower than any previously reported. On average, the survival
of a replacement mutation is almost twice as probable as the
survival of a synonymous mutation. Overall, this signifies
that selection favors change in this region, although the
absence of stop codons and the conservation of a number of
amino acids, including the cysteine residues spanning the V3
loop, indicate that the extent of change possible is limited.
Although positive selection for change is unusual, it has been
observed in major histocompatibility complex proteins (13)
and in mammalian and avian serine protease inhibitors (12,
15). For the specific requirements of increased diversity of
antigenic recognition by the major histocompatibility com-
plex molecule, and for defense against a range of bacterial
proteases in the latter example, positive selection appears to
confer a selective advantage for the mutated sequences.
Given the known involvement of V3 in virus neutralization
(28), selection for change in V3 suggests that the selective
force is the immune defense system.
Consequences of sequence change in the hypervariable
regions of env. Several areas of the env gene product have
been shown to be antigenic upon natural infection and upon
vaccination (8, 9, 19, 26-28, 36). The V3 loop and regions in
gp4l have been positively identified as targets of antibody-
mediated neutralization or cytotoxic T-lymphocyte (CTL)
killing. Both immune effector functions are sensitive to
sequence variation around the crown of the V3 loop, i.e.,
either side of the relatively well conserved GPGR central
sequence. The specificity of the CTL response can be
determined in large part by the amino acids immediately
downstream of GPGR (36), while residues immediately
upstream of GPGR have been shown to be important in
antibody-mediated neutralization (10, 19, 22). Considerable
sequence variation is found in both of these sites in the
sequences obtained in this study. Both tyrosine and valine
are found at a position critical for CTL recognition (36), not
only in different samples but also within the same sample
(e.g., p87 and p91; Fig. 6C). A histidine substitution at this
site (p77) would also be expected to modify the epitope.
Other amino acid changes are concentrated at the site of
B-cell recognition, with most samples containing at least two
different sequences. There are also mutations in the central
GPGR motif (p12, p74, and p77) that could disrupt the ,B turn
at this site (22) and probably abolish immune recognition.
This high level of variation in V3 predicts the existence of a
wide range of neutralization serotypes in many of the pa-
tients. Sera and CTLs from such individuals may be ex-
pected to be reactive against a range of standard viral
isolates. The broadening specificity of neutralizing antibod-
ies with time seen in HIV-seropositve individuals (1) may be
due to the de novo appearance of V3 serotypes upon
long-term infection.
Neutralizing antibodies that bind to V4 and V5 regions
have not been described, and the contribution of these two
regions to the overall antigenicity of gpl20 is uncertain.
However, both regions have been identified as being poten-
tially antigenic on the basis of surface probability and
hydrophilicity (23). The absence of linear epitopes in either
region is shown by the poor serological reactivity with
synthetic oligopeptides containing V4 and V5 sequences and
the low immunogenicity of such peptides upon vaccination
(25). This does not rule out the possibility that V4 and V5
form conformational epitopes that are not mimicked by
synthetic peptides. Furthermore, the antigenicity of both
areas in vivo may be altered by posttranslational additions of
N-linked oligosaccharide groups. gpl20 is heavily glycosy-
lated at N-linked but not at 0-linked sites (14), and all 24
potential N-linked sites are glycosylated when recombinant
HIVHTLVIIIB gpl2O is expressed in mammalian cells (T. J.
Gregory, C. K. Leonard, L. Riddle, J. R. Thomas, R. J.
Harris, and M. W. Spellman, J. Cell. Biochem. 14D:151,
1990). N-linked glycosylation can mask potential peptide
epitopes (2, 32) or themselves form conformational epitopes
(2, 7, 33, 35). Glycosylation of V4 and V5 may therefore
serve to mask the relatively invariant intervening CD4
binding region. The absence of monoclonal antibodies to V4,
C4, and V5 may thus be a reflection of the effectiveness of
glycosylation in masking potential epitopes rather than a
supposed low antigenicity of the underlying peptide se-
quences. The preponderance of glycosylation sites in the
hypervariable regions, and the major alteration in the posi-
tion and number of such sites by amino acid substitution and
sequence reduplication, could therefore be interpreted as an
evolutionary response by HIV to evade the immune system.
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